Technical Data
C9097-15O
Cytokeratin 16
Description:
Cytokeratin 16 expression is particularly pronounced in conditions such as wound healing, psoriasis and also in some carcinomas such as basal cell carcinoma.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry (Frozen and Paraffin): 1:20-1:40 Paraffin sections require antigen retrieval using heat treatment methods prior to staining. Sodium Citrate buffer pH 6.0 is recommended for this purpose.
Optimal dilutions to be determined by the researcher.

Hybridoma:
Spleen cells from immunized mice were fused with cells of the mouse SP2/0-Ag14 myeloma cell line.

Positive Control:
Non-melanocytic skin cancer, basal cell carcinoma

Recommended Secondary Reagents:
I1904-65W: IgG, F(ab)2 (HRP) Pab RbxMo
I1904-66C: IgG, F(ab)2, X-Adsorbed (HRP) Pab RbxMo

Recommended Negative Controls:
I1904-79G: IgG1, Mouse, Negative Control

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG16A401Supernatant
SizeStorageShippingSourceHost
200ul-20CBlue IceHumanMouse
Concentration:
Not Determined
Immunogen:
Synthetic peptide derived from the C-terminus of human cytokeratin 16.
Purity:
Tissue Culture Supernatant
Form
Supplied as a liquid, 0.09% sodium azide.
Specificity:
Recognizes human cytokeratin 16, expressed in areas where there is high turnover of keratinocytes.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Markey, A.C. et al. (1992). Keratin expression in basal cell carcinomas. Br. J. Dermatol. 126: 154-160.2. 2. Wetzels, R.H.W. et al. (1991). Basal cell-specific and hyperproliferation related keratins in human breast cancer. Am. J. Pathol. 138: 751-763..